SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas reported Baxfendy sales have traders questioning how quickly the new aldosterone-inhibitor class can gain coverage and commercial traction, weighing on expectations for Mineralys planned launch. Some see the early sales as a normal reimbursement ramp for a chronic treatment, while others worry that a slow launch and competition could constrain lorundrostats sales potential.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has put pressure on Precigens PAPZIMEOS and raised concerns about competition. Traders debate the threat to Precigens sales against its first-mover and full-approval advantages, while noting Voceryqs accelerated-approval status and commercialization hurdles.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is drawing attention after Piper Sandler lowered its price target, keeping a Neutral rating while pointing to concerns that networking growth may be peaking and valuations could compress. Traders are debating whether the selloff is justified or an overreaction, with bulls pointing to continued AI-infrastructure demand and bears focused on weak price action.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Traders are focused on reported MoneyGram connectivity and Zebecs broader payroll and payments expansion, viewing real-world adoption and potential token demand as bullish catalysts. Others remain skeptical, pointing to weak price follow-through and questioning whether business growth will translate into sustained ZBCN usage or buybacks.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Positive Phase 3 data for Amgens IMDELLTRAImfinzi combination in small-cell lung cancer is supporting bullish attention as shares reach a fresh high, with traders also focused on the upcoming earnings report and a Sjgrens disease readout. Put-heavy options activity is being debated as possible earnings hedging rather than a clear bearish bet, alongside call buying and momentum interest.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIMs attention is centered on its higher full-year outlook, which traders link to persistently strong container freight rates and demand, boosting expectations for earnings and dividends. The community is also debating whether Hapag-Lloyds acquisition can clear Israeli regulatory objections, with some favoring a sale and others preferring standalone cash generation and dividends.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high ahead of the expected Q3 report has traders focused on BRIUMVIs sales momentum, while unconfirmed buyout speculation and call-heavy options activity add to the buzz. The community is split on whether the rally reflects earnings positioning and potential short covering or anticipation of a deal; no buyout has been confirmed.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devons agreed sale of its Eagle Ford assets to Crescent is driving attention, following earlier speculation about asset divestitures and pressure to streamline the company after its Coterra merger. Traders are divided on whether the sale improves focus and capital allocation, with some questioning why the shares have not responded more strongly.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention as traders react to a sharp tech-led Nasdaq selloff and falling futures, with worries about AI spending returns and disappointing tech results reinforcing bearish bets. Many are buying or holding SQQQ as a hedge, while others warn that the leveraged ETF can reverse quickly; separate Iran-deal chatter remains unverified and contested.

3M Co. is a technology company, which engages in manufacturing industrial, safety, and consumer products. It operates through the following segments: Safety and Industrial, Transportation and Electronics, Consumer, and Corporate. The Safety and Industrial segment consists of personal safety, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules. The Transportation and Electronics segment includes electronics, automotive and aerospace, commercial solutions, advanced materials, and transportation safety. The Consumer segment covers consumer healthcare, home care, home improvement, and stationery and office products, such as consumer bandages, braces, supports, respirators, cleaning products, retail abrasives, picture hanging, and consumer air quality solutions. The Corporate segment refers to special items and other corporate expenses. The company was founded by Henry S. Bryan, Hermon W. Cable, John Dwan, William A. McGonagle, and J. Danley Budd in 1902 and is headquartered in St. Paul, MN.

3M Co.

3Ms earnings beat and raised outlook, alongside its expanded Amazon data-center partnership, are driving attention. Bulls see the deal as a growth opportunity, while skeptics note that Amazons purchase threshold is conditional and call the rally overdone, with bearish traders discussing puts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tevogen CEO Says ‘Actively Evaluating’ Potential Acquisitions 

Equity

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.


Tevogen Bio (NASDAQ:TVGN) Sets New 12-Month Low - Here's What Happened

Tevogen Bio (NASDAQ:TVGN) Reaches New 12-Month Low - Should You Sell...

Tevogen Shares Take Further Beating On Gauging Deal With Apozel Pharmaceuticals

If the deal goes through, it could provide Tevogen with an established generics platform, the company said.

Tevogen Bio (TVGN) to Release Earnings on Wednesday

Tevogen Bio (NASDAQ:TVGN) will be releasing earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Tevogen Bio (NASDAQ:TVGN) Trading 7.9% Higher - Should You Buy?

Tevogen Bio (NASDAQ:TVGN) Stock Price Up 7.9% - Should You Buy...

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's Why

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Time to Sell?

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Price Target Cut to $5.00 by Analysts at D. Boral Capital

D. Boral Capital decreased their target price on shares of Tevogen Bio from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday...

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

Tevogen Bio (NASDAQ:TVGN - Get Free Report) posted its earnings results on Friday. The company reported ($0.03) earnings per share for the quarter...

Buy When There’s Blood in the Streets: Why the DeepSeek Rout May Be Good News for Microsoft Stock

Microsoft’s stock presents a buying opportunity due to its strong financials, strategic partnerships, and potential to benefit from cheaper AI models in the long run.

Tevogen, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

Tevogen Inc.

Bullish Sentiment

Tevogen CEO Ryan Saadi said in a letter to shareholders on Friday that the company is “actively evaluating” potential acquisitions to drive value.“If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time,” the CEO said.As <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/06/3251264/0/en/Letter-to-Shareholders-from-CEO-Dr-Ryan-Saadi.html">per</a> the CEO, the combined entities under consideration for acquisition may generate aggregate annual revenues in excess of $50 million, based on preliminary evaluations.<h2 class="st-heading-2">Proposed Deals</h2>The CEO’s letter comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.If the deal with Apozel goes through, it could provide Tevogen with an established generics platform, the company had said. This includes 11 FDA-approved generic products for the U.S. market and others awaiting approval by the FDA or currently under development.Tevogen is also actively considering other transactions, the company said earlier this week, while expressing its interest in domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers.Last month, the company signed another letter of intent to evaluate a deal with a global contract research organization.Earlier this week, the company also said that its Board has approved a reverse stock split of its common stock at a ratio of 50 for 1 to regain compliance with Nasdaq’s $1 minimum bid price requirement. The stock began trading on a split-adjusted basis on Friday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVGN stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/TVGN">TVGN stock</a> has erased nearly 87% of its value over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-lnth-stock-up-after-hours/cZdLQ3SRI4B">Why Is LNTH Stock Up After Hours?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.

iShares Micro-Cap ETF

iShares Russell 2000 ETF

Tevogen Bio Holdings Inc.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$5.90
Prev Close	$6.05
Open	$5.95
Dividend Yield	0.00%
50-Day Moving Average	$6.97
Beta	1.08
Avg. Volume	8,118.35
PE Ratio	-1.01

52-Week High	$32.50
52-Week Low	$3.64
Market Capitalization	$38.42M
EPS (Annual)	-$8.08
Price to Book	-1.42
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TVGN Fundamentals